4D Molecular Therapeutics (FDMT) EBT Margin (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly EBT Margin of 3114.9% for Q1 2026, up 35002081.0% year-over-year from N/an in Q1 2025, and down 14809.3% quarter-over-quarter from 21.18% in Q4 2025.
Powered by 
Analysis
4D Molecular Therapeutics (FDMT) EBT Margin (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported EBT Margin for 7 consecutive years, with 3114.9% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin rose 35002081.0% year-over-year to 3114.9%; the TTM figure through Mar 2026 stood at 286.32% (up 97098759.0% YoY), while the FY2025 annual figure was 350.46%, up 78039278.0% from the prior year.
- EBT Margin retreated to 3114.9% in Q1 2026 per FDMT's latest filing, from 21.18% in the prior quarter.
- Across five years, EBT Margin topped out at 174063.16% in Q4 2023 and bottomed at 5055000.0% in Q4 2024.
- Historically, EBT Margin has averaged 567804.6% across 5 years, with a median of 21127.78% in 2022.
- Annual changes were most pronounced in 2024 — EBT Margin sank 522906316 bps — and 2025, when it surged 505502118 bps.
- 4D Molecular Therapeutics' EBT Margin stood at 2428.39% in 2022, then jumped by 7268 bps to 174063.16% in 2023, then plunged by 3004 bps to 5055000.0% in 2024, then soared by 100 bps to 21.18% in 2025, then sank by 14809 bps to 3114.9% in 2026.
- Business Quant data shows FDMT's EBT Margin at 3114.9% in Q1 2026, 21.18% in Q4 2025, and 95417.78% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | 4D Molecular Therapeutics | 1.05 Bn | 692.04 Mn | - | -1,924.62% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,924.62% |
| Mar 31, 2026 | -2,445.91% |
| Dec 31, 2025 | 22.82% |
| Sep 30, 2025 | -63,172.22% |
| Jun 30, 2025 | -363,980.00% |
| Mar 31, 2025 | -382,271.43% |
| Dec 31, 2024 | -4,965,000.00% |
| Sep 30, 2024 | -1,461,400.00% |
| Jun 30, 2024 | -852,800.00% |
| Mar 31, 2024 | -136,646.43% |
| Dec 31, 2023 | 169,852.63% |
| Sep 30, 2023 | -49.98% |
| Jun 30, 2023 | -13,188.70% |
| Mar 31, 2023 | -9,791.95% |
| Dec 31, 2022 | -2,195.83% |
| Sep 30, 2022 | -5,140.00% |
| Jun 30, 2022 | -17,797.53% |
| Mar 31, 2022 | -2,246.92% |
| Dec 31, 2021 | -27,256.52% |
| Sep 30, 2021 | -1,627.09% |